Duda Lab
Kong N, Tao W, Ling X, Wang J, Xiao Y, Shi S, Ji X, Shajii A, Gan ST, Kim NY, Duda DG, Xie T, Farokhzad OC, Shi J
Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.
Sci Transl Med. 2019;11(523):ePub - PMID: 31852795 - PMCID: PMC7024563 - DOI: 10.1126/scitranslmed.aaw1565
Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
J Clin Oncol. 2019;37(35):3446-3454 - PMID: 31626572 - PMCID: PMC7098833 - DOI: 10.1200/JCO.19.01367
Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, Chukwueke UN, Beroukhim R, Doherty L, Laub CK, LaFrankie D, Fontana B, Stefanik J, Ruland S, Caruso V, Bruno J, Ligon K, Reardon DA, Wen PY
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Cancer Med. 2019;8(13):5988-5994 - PMID: 31444999 - PMCID: PMC6792497 - DOI: 10.1002/cam4.2505
Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, Duda DG, Guimaraes AR, Hong TS, Bortfeld TR, Seco J
Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy.
Clin Transl Radiat Oncol. 2019;18:113-119 - PMID: 31341986 - PMCID: PMC6630151 - DOI: 10.1016/j.ctro.2019.04.013
Saftoiu A, Bhutani MS, Itoi T, Arcidiacono PG, Bories E, Cazacu IM, Constantin A, Coronel E, Dietrich CF, Duda DG, Garcia JI, Hocke M, Ignee A, Jenssen C, Jinga M, Khor C, Oppong KW, Pereira S, Petrone MC, Santo E, Seicean A, Seo DW, Siyu S, Vilmann P, Waxman I, Yeaton P
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol.
Endosc Ultrasound. 2019;8(4):235-240 - PMID: 31249159 - PMCID: PMC6714481 - DOI: 10.4103/eus.eus_16_19
Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Sci Rep. 2019;9(1):8721 - PMID: 31197238 - PMCID: PMC6565804 - DOI: 10.1038/s41598-019-44365-2
Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
JAMA Oncol. 2019;5(7):1020-1027 - PMID: 31145418 - PMCID: PMC6547247 - DOI: 10.1001/jamaoncol.2019.0892
Amoozgar Z, Jain RK, Duda DG
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?
Cancer Res. 2019;79(9):2104-2106 - PMID: 31043429 - PMCID: PMC6601607 - DOI: 10.1158/0008-5472.CAN-19-0749
Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer. 2019;125(13):2213-2221 - PMID: 30913304 - PMCID: PMC6763367 - DOI: 10.1002/cncr.32029
Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK
Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.
NPJ Breast Cancer. 2019;5:4 - PMID: 30675514 - PMCID: PMC6333771 - DOI: 10.1038/s41523-018-0100-8
10